MedTrace Logo

Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07

NCT01281137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2021-10-06

Study results available
· View outcomes & findings →

Summary

RATIONALE: Studying samples of blood in the laboratory from patients receiving treatment for cancer may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying changes in estrogen levels and grip strength in postmenopausal women who have received 4 to 6 years of hormone therapy for breast cancer and are currently receiving letrozole on clinical trial IBCSG-35-07.

Conditions

Interventions

GENETIC

polymorphism analysis

SNPs will be genotyped in whole blood samples taken at baseline.

OTHER

laboratory biomarker analysis

Biomarkers will be assessed in blood and serum samples at different time points.

PROCEDURE

quality-of-life assessment

Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.

Sponsors & Collaborators

  • ETOP IBCSG Partners Foundation

    lead NETWORK

Principal Investigators

  • Jacquie Chirgwin, MD · Box Hill Hospital

  • Guy Jerusalem, MD, PhD · CHU Liege - Domaine Universitaire du Sart Tilman

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2019-05-15
Completion
2019-05-15

Countries

  • Australia
  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281137 on ClinicalTrials.gov